He's 34, lean, no diabetes. Why he takes tirzepatide anyway.

Dr. Brad Stanfield takes 1.25 mg of tirzepatide weekly despite being outside every trial that says he should. Four discoveries in two years changed the calculation.

Why I Take Low-Dose Tirzepatide (& Not Retatrutide)

Brad Stanfield is 34, lean, and does not have diabetes. No randomized trial has enrolled someone like him. Not SELECT, not FLOW, not SURPASS. Every GLP-1 study you have heard of tested people with type 2 diabetes, obesity, kidney disease or established heart disease.

He injects 1.25 mg of tirzepatide every week anyway.

The reason is not weight loss. He has lost 3 kg in nine months, which was not the goal. The reason is four discoveries that emerged between 2021 and 2024, none of which were supposed to happen. Each one changed what the drug was thought to do, and each one widened the gap between what the trials enrolled for and what the medication seemed to offer.

1. Weight loss was not the whole story

When John Eng found GLP-1 in the saliva of the Gila monster in the early 1990s, it was supposed to lower blood sugar. He was an endocrinologist at the Bronx VA working on lizard venoms in his spare time. The peptide he isolated acted on the same receptor as human GLP-1 but lasted much longer in the body.

In the early diabetes trials, patients did lower their blood sugar, as expected. But they also started losing significant amounts of weight. Enough for doctors to notice.

By the mid-2010s, the SCALE trial confirmed that liraglutide caused serious weight loss. By 2021, the STEP program tested semaglutide at 2.4 mg for obesity, not diabetes, and patients lost around 15% of their body weight.

The field assumed every benefit from here would be downstream of the weight coming off. That is not what the next trials found.

2. The cardiovascular benefit did not track with weight loss

November 2023. The SELECT trial enrolled more than 17,000 adults who were overweight or obese with established heart disease but no diabetes. They were randomized to weekly semaglutide or placebo.

A little more than three years later, semaglutide cut major cardiovascular events by 20%.

When the researchers ran the numbers separately for people who lost a lot of weight versus very little, a chunk of the cardiovascular benefit did not track with how much weight came off. The GLP-1 appeared to offer cardiovascular benefits beyond the weight loss effect.

3. The kidney benefit was unrelated to body weight

May 2024. The FLOW trial involved about 3,500 adults with type 2 diabetes and chronic kidney disease. Semaglutide versus placebo.

The primary outcome, a combination of kidney failure rates, large eGFR drops, and kidney or cardiovascular death, dropped by 24%.

The authors said something specific. The effect on kidney health was unrelated to changes in body weight. The weight loss was not the whole story.

Why this matters if you haven’t started yet: New evidence also shows GLP-1 medications are associated with a reduction in cancer progression, though Stanfield did not detail the data.

4. Cartilage regrew, and it was not from losing weight

Cartilage has no blood supply, no nerves, and no efficient way to deliver nutrients. Once damaged, it is severely limited in its ability to repair itself.

Then patients on Ozempic started saying their joints felt better. Not just less pain from carrying less weight. Something else.

The STEP 9 trial, published in the New England Journal of Medicine in 2024, enrolled 407 patients with obesity and knee osteoarthritis. After 68 weeks, pain scores dropped by 42 points in the semaglutide group compared to 28 in placebo. Patients also lost 13.7% of their body weight. Case closed, or so it seemed.

A team at the Shenzhen Institutes of Advanced Technology, led by Dr. Dai Chen, was not satisfied. They took mice with osteoarthritis and split them into two groups. One received semaglutide. The other was pair-fed, meaning they were given restricted calories so they lost the same amount of weight as the semaglutide group. Same weight loss, no drug.

If the joint improvements were just weight loss, both groups should look the same. They did not.

The pair-fed mice lost the same weight but their cartilage kept deteriorating. Only in the semaglutide group did cartilage stay preserved, inflammation reduce, and bone spurs shrink. Same weight loss, completely different outcome in the joints.

This controlled experiment demonstrates that semaglutide's protective effect on cartilage in osteoarthritis is independent of weight loss and challenges the traditional belief that osteoarthritis improvement relies solely on weight reduction.Dr Brad Stanfield

How semaglutide repairs cartilage

Cartilage cells, called chondrocytes, need energy to maintain and repair tissue. In osteoarthritis, those cells get stuck running on an inefficient fuel source. Think of a factory running on a sputtering generator. Barely enough energy to keep the lights on, not nearly enough to rebuild anything.

Semaglutide flips a switch inside those cells. It upgrades them to a clean, efficient energy source that produces dramatically more energy, enough to actually start repairing. It is activated by GLP-1 receptors on the cartilage cells. Researchers were not anticipating GLP-1 receptors would be on cartilage cells. But there they are.

Chen's team ran a pilot clinical study. Twenty patients aged 50 to 75, all with obesity and knee osteoarthritis. Half received standard treatment with hyaluronic acid injections. The other half received hyaluronic acid plus weekly semaglutide.

After 24 weeks, MRI scans showed the semaglutide group had an average 17% increase in cartilage thickness, suggesting regeneration. The control group lost about 1%. The thickened cartilage was visible in weight-bearing areas of the knee, the areas that take the most punishment. Patients also experienced reduced pain and improved joint function.

Why this matters if you haven’t started yet: The discovery arc also includes benefits for the liver and for addiction, though Stanfield did not detail those findings.

5. Why tirzepatide instead of semaglutide

Everything discussed so far is evidence for GLP-1 medications. Stanfield chose tirzepatide, which is a combination of GLP-1 and GIP. The reason comes from SURPASS-CVOT.

The trial was published in two stages. The primary outcome in the New England Journal of Medicine in December 2025, and a follow-up cardiovascular analysis in JAMA Cardiology in March 2026. Tirzepatide, which is GLP-1 plus GIP, versus dulaglutide, which is a pure GLP-1. Thirteen thousand patients with type 2 diabetes and established heart disease, followed for just over four years.

The primary endpoint was the classic three-point MACE: cardiovascular death, heart attacks, or strokes. Tirzepatide did not beat dulaglutide on that endpoint. It cleared the no-worse-than bar cleanly, but on the harder question of is it actually better, the result came in short of the threshold the researchers had committed to before the study started. By their own rules going in, it counts as a miss.

But the same investigators ran a post-hoc analysis in JAMA Cardiology in 2026. They widened the endpoint to six components, adding heart failure hospitalization, coronary revascularization, all-cause death, and a renal composite to the original three. On that wider endpoint, tirzepatide reduced risk by 16% relative to dulaglutide.

For Stanfield personally, that was enough to want the combination of GLP-1 and GIP compared to just GLP-1.

6. Why tirzepatide instead of retatrutide

Retatrutide is a triple agonist. It has a third component that acts on glucagon receptors. Glucagon agonism increases metabolic rate. For an obesity drug at a population level, that is a feature. For Stanfield, trying to maintain lean muscle mass and not burn any of it, pushing energy expenditure up is the wrong direction.

With that rise in metabolic rate comes a dose-dependent rise in resting heart rate. Three to seven beats per minute in a phase 2 trial. Tirzepatide does raise heart rate, typically about two to four beats per minute, but not as much as retatrutide.

With that rise in metabolic rate, there are also concerns about the cardiovascular risk profile with retatrutide. The data is still pending.

Stanfield does not want to take something that speeds up his metabolic rate when he is not trying to lose weight.

7. What happened when he took it

Since using tirzepatide, Stanfield has noticed a significant drop in food noise. It is way easier to stick to a healthy diet because the cravings for junk food are just gone.

He has genetically high blood pressure. Since using tirzepatide, he has managed to cut his blood pressure medication doses in half.

It made him feel pretty rubbish when he first started. He felt nauseous and tired. But with each injection, the side effects lessened. Now he has no side effects whatsoever.

He looks after his muscle mass via resistance exercise and good protein intake. He has lost about 3 kg over a nine-month period.

On a GLP-1, daily calorie intake typically drops by 16 to 39%. The American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society all suggest considering a multivitamin and mineral tablet. That is part of the reason Stanfield takes a multivitamin every day.

I have noticed a significant drop in food noise. It's way easier to stick to a healthy diet because the cravings for junk food, they're just gone.Dr Brad Stanfield

8. The safety concerns he weighed

There was a concern about pancreatitis. From the real-world data, there has been no increase.

There is also no signal of increased risk of thyroid cancer from the real-world data.

The FDA and EMA, the European drug regulator, both reviewed the suicidal signal in 2024 and found no causal link.

The final concern is micronutrient levels. Stanfield is eating less food since being on low-dose tirzepatide, which is why he takes a multivitamin. But he is clear: just because he takes a supplement does not mean you should.

None of these studies enrolled lean, non-diabetic adults. The bet Stanfield is making is narrower. Across several studies, these drugs seem to produce some biological effects that are partly independent of the weight loss effect itself. He is interested in exposing himself to those potential mechanisms.

He is not the first physician to publicly disclose this. Dr. Michael Albert, a US internist, wrote about taking low-dose tirzepatide for two years in March 2026 and framed it as a personal choice, not a recommendation. Stanfield is doing the same. He is happy with his bet on low-dose tirzepatide and plans on taking it long-term.

Questions people ask

Can you take tirzepatide if you are not overweight or diabetic?

No randomized trial has studied lean, non-diabetic adults on tirzepatide. Dr. Stanfield takes 1.25 mg weekly as a personal choice based on emerging evidence of cardiovascular, kidney, and joint benefits that appear partly independent of weight loss. This is off-label use and not supported by clinical trial data for his demographic.

Does tirzepatide help with joint pain beyond weight loss?

Yes, according to preclinical and early clinical data. In a controlled mouse study, semaglutide preserved cartilage and reduced inflammation even in mice that lost the same amount of weight without the drug. A pilot human study showed a 17% increase in cartilage thickness after 24 weeks on semaglutide plus hyaluronic acid, compared to 1% loss in controls.

Why would someone choose tirzepatide over retatrutide?

Retatrutide is a triple agonist that increases metabolic rate through glucagon receptor activation, which can raise resting heart rate by three to seven beats per minute. Tirzepatide raises heart rate less, about two to four beats per minute. For someone not trying to lose weight and concerned about cardiovascular risk, tirzepatide may be preferable until more long-term data on retatrutide is available.

DB
Dr Brad Stanfield

Dr. Brad Stanfield is a 34-year-old general practitioner who has been documenting his personal use of low-dose tirzepatide for nine months. He takes 1.25 mg weekly, has lost 3 kg, and cut his blood pressure medication in half. 414,060 views on the original video.

Watch the original on YouTube →

Trending Topics

Free, from GLP‑1 Classified

Thinking about a GLP‑1? Read our guide before you start.

The questions to ask, the costs nobody mentions, and what the first month really feels like. Plus a short weekly letter for people on, or considering, a GLP‑1. We are not a pharmacy or a telehealth brand. We work for you, not for them.

No spam. Unsubscribe any time.